This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
IQVIA (IQV) International Revenue Performance Explored
by Zacks Equity Research
Explore how IQVIA's (IQV) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
S&P Global Q4 Earnings & Revenues Surpass Estimates, Increase Y/Y
by Zacks Equity Research
SPGI's top line benefits from an improved segmental performance in the fourth quarter of 2024.
Top Research Reports for Procter & Gamble, Boston Scientific & ConocoPhillips
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Boston Scientific Corporation (BSX) and ConocoPhillips (COP), as well as a micro-cap stock Kewaunee Scientific Corporation (KEQU).
IQVIA Earnings & Revenues Surpass Estimates in Q4, Increase Y/Y
by Zacks Equity Research
Growth in the Research and Development, and Technology and Analytics segments aids IQV's top line in the fourth quarter of 2024.
Here's What Key Metrics Tell Us About IQVIA (IQV) Q4 Earnings
by Zacks Equity Research
Although the revenue and EPS for IQVIA (IQV) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
IQVIA Holdings (IQV) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
IQVIA (IQV) delivered earnings and revenue surprises of 0.65% and 0.89%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
IQVIA Gears Up to Report Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
IQV's top line in the fourth quarter of 2024 is expected to have benefited from the rising use of GenAI to provide crucial insights.
Here's Why IQVIA Holdings (IQV) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
IQVIA Holdings (IQV) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Unlocking Q4 Potential of IQVIA (IQV): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of IQVIA (IQV) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Will IQVIA (IQV) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
IQVIA (IQV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Penumbra (PEN) Surges 6.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
IQVIA Benefits From Global IT Infrastructure Amid Low Liquidity
by Zacks Equity Research
The IQV stock gains from its $330-billion addressable market and an enormous trove of data, which is its distinguishing asset.
IQVIA (IQV) Surges 3.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
IQVIA (IQV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why You Should Retain IQVIA Holdings Stock in Your Portfolio Now
by Zacks Equity Research
IQV is known for its innovative use of technology and data analytics.
Green Dot Stock Appreciates 4% Despite Earnings Miss in Q3
by Zacks Equity Research
GDOT's third-quarter 2024 revenues increase primarily from the performance of the B2B Services segment.
Envestnet's Shares Barely Move After Q3 Earnings Beat, Revenues Lag
by Zacks Equity Research
ENV's top line in the third quarter of 2024 benefits from improved segmental performance.
MARA Holdings Set to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
The commencement of the Kaspa mining operations is likely to have benefited MARA's top line in the third quarter of 2024.
Insperity Stock Appreciates 5% After Reporting Q3 Earnings Beat
by Zacks Equity Research
NSP witnesses a rise in WSEE in the third quarter of 2024.
Interpreting IQVIA (IQV) International Revenue Trends
by Zacks Equity Research
Evaluate IQVIA's (IQV) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
IQVIA (IQV) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for IQVIA (IQV) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
IQVIA Earnings & Revenues Surpass Estimates in Q3, Increase Y/Y
by Zacks Equity Research
Strength in the Research and Development, and Technology and Analytics segments drives IQV's top line in the third quarter of 2024.
Veeva Systems Collaborates With Walgreens to Improve Patient Outcomes
by Zacks Equity Research
VEEV partners with Walgreens to provide better patient outcomes to life sciences companies.